# Performance of Contrast-Enhanced Ultrasound in Thyroid Nodules: Review of Current State and Future Perspectives

**Authors:** Maija Radzina, Madara Ratniece, Davis Simanis Putrins, Laura Saule, Vito Cantisani

PMC · DOI: 10.3390/cancers13215469 · Cancers · 2021-10-30

## TL;DR

Contrast-enhanced ultrasound (CEUS) improves thyroid nodule diagnosis by analyzing blood flow patterns, helping distinguish benign from malignant nodules and guiding treatment.

## Contribution

This paper reviews CEUS's current performance and potential in thyroid nodule diagnosis and treatment guidance.

## Key findings

- Combining CEUS parameters like hypo-enhancement and wash-in/wash-out curves improves malignancy detection accuracy.
- Homogeneous and intense enhancement patterns are typically associated with benign thyroid nodules.
- CEUS can guide ablation procedures and assess treatment efficacy in thyroid nodules and lymph nodes.

## Abstract

Ultrasound has been used as baseline imaging for thyroid nodules for decades; nevertheless, no single feature is sensitive or specific enough to exclude or confirm thyroid malignancy. Therefore, clinical practice and research still focus on less invasive diagnostic patterns to reduce unnecessary fine-needle aspiration biopsies or surgery. The main advantage of CEUS is the ability to assess the sequence and intensity of vascular perfusion and hemodynamics in the thyroid nodule, thus providing real-time characterization of nodule features, and considered a valuable new approach in the determination of benign vs. malignant nodules. In addition, contrast agents used in CEUS can help to guide treatment planning for minimally invasive procedures (e.g., ablation) and to provide accurate follow-up imaging to assess treatment efficacy in both benign and malignant nodules and associated lymph nodes. Examination protocol has almost reached standardization, although there are numerous controversies reported about the interpretation of qualitative and quantitative patterns that would require a systematic approach. This literature and current state review of CEUS in thyroid nodules address the existing concepts and highlights of the future perspectives.

Ultrasound has been established as a baseline imaging technique for thyroid nodules. The main advantage of adding CEUS is the ability to assess the sequence and intensity of vascular perfusion and hemodynamics in the thyroid nodule, thus providing real-time characterization of nodule features, considered a valuable new approach in the determination of benign vs. malignant nodules. Original studies, reviews and six meta-analyses were included in this article. A total of 624 studies were retrieved, and 107 were included in the study. As recognized for thyroid nodule malignancy risk stratification by US, for acceptable accuracy in malignancy a combination of several CEUS parameters should be applied: hypo-enhancement, heterogeneous, peripheral irregular enhancement in combination with internal enhancement patterns, and slow wash-in and wash-out curve lower than in normal thyroid tissue. In contrast, homogeneous, intense enhancement with smooth rim enhancement and “fast-in and slow-out” are indicative of the benignity of the thyroid nodule. Even though overlapping features require standardization, with further research, CEUS may achieve reliable performance in detecting or excluding thyroid cancer. It can also play an operative role in guiding ablation procedures of benign and malignant thyroid nodules and metastatic lymph nodes, and providing accurate follow-up imaging to assess treatment efficacy.

## Linked entities

- **Diseases:** thyroid cancer (MONDO:0002108)

## Full-text entities

- **Genes:** CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}
- **Diseases:** hypoechoic lesion (MESH:D009059), medullary carcinoma (MESH:D018276), NHL (MESH:D008228), CD (MESH:D003424), autoimmune thyroiditis (MESH:D013967), follicular thyroid neoplasms (MESH:D013964), Adenomas (MESH:D000236), nodal involvement (MESH:D013611), hemorrhage (MESH:D006470), hyperthyroidism (MESH:D006980), atrophic (MESH:D020966), nodular goiter (MESH:D006044), Benign Thyroid Lesions (MESH:D013959), MEN2 (MESH:D018813), MTC (MESH:C536914), microcarcinomas (MESH:C563277), squamoid-cell tumors (MESH:D005935), Hurthle cell neoplasia (MESH:C536913), inflammation in the thyroid gland (MESH:D007249), PTL (MESH:D008223), Papillary carcinoma (MESH:D002291), ATC (MESH:D065646), calcification (MESH:D002114), Thyroid (MESH:D013966), benign lesion (MESH:D001932), thyroid malignant tumors (MESH:D018198), endocrine disorder (MESH:D004700), PTC (MESH:D000077273), Follicular hyperplasia (MESH:D006965), arteriovenous fistula (MESH:D001164), nodes (MESH:D012804), cancer (MESH:D009369), Thyroid Nodules (MESH:D016606), Hashimoto and Riedel's thyroiditis (MESH:D050031), FTC (MESH:D018263), hypothyroidism (MESH:D007037), necrosis (MESH:D009336), fibrosis (MESH:D005355), nodal metastatic involvement (MESH:D000092182), Multinodular goiter (MESH:C564546), subacute thyroiditis (MESH:D013968), Goiter (MESH:D006042)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8582579/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8582579/full.md

## References

113 references — full list in the complete paper: https://tomesphere.com/paper/PMC8582579/full.md

---
Source: https://tomesphere.com/paper/PMC8582579